OXGENE introduces SLIM platform for discovery of antibodies against membrane proteins
The novel self-labelling mammalian display method identifies antibodies against membrane proteins in their native configuration
The novel self-labelling mammalian display method identifies antibodies against membrane proteins in their native configuration
Guest editorial: Technology to meet the needs of faster vaccine development
Watch this on demand webinar to learn about SpyTag-SpyCatcher technology and how TrailBlazer Antibodies can transform your assay development
Working with the UK government, first vaccinations are to begin early in the new year
The real-time RT-PCR assay can simultaneously detect and differentiate 8 target genes, the first and only test to do so in the world
Top talks and resources exploring the latest research and methods in the field are now available on demand
Dr. Jacqueline Barnett and Dr. Joel Allainguillaume discuss their work to develop handheld detectors to combat the spread of cacao swollen shoot virus and arrest the decline in the cocoa industry
Elecsys Anti-SARS-CoV-2 S test specifically detects antibodies against the SARS- CoV-2 spike protein
Explore ways to improve time to result in critical pathways such as sepsis
In a 17-4 vote, the FDA vaccine advisory committee recommended that Pfizer/BioNTech’s COVID-19 vaccine should be distributed to the U.S.
Watch this on-demand webinar to learn how COVID immune responses can be assessed using a novel microfluidic in-solution immunoassay platform
Access SARS-CoV-2 IgG II test is a semi-quantitative assay that measures patient’s relative level of antibodies in response to a previous SARS-CoV-2 infection
Phase 3 interim analysis including 131 Covid-19 cases indicates that the vaccine is 70.4% effective when combining data from two dosing regimens
Two different dosing regimens demonstrated efficacy with one showing a better profile
The collaboration aims to secure manufacturing and testing capacity in the next phase of the pandemic
As SARS-CoV-2 vaccines become available, Siemens Healthineers is ready with fully automated antibody tests that can be used to help inform whether broad vaccination programs are working